In ALS, Respiratory Measure Predicts Pace of Disease
Slow vital capacity, a measure of respiratory function, predicted the rate of disease progression in ALS patients, suggesting the test could be used as a primary endpoint in clinical trials.
6400 RESULTS
Sort By:
Slow vital capacity, a measure of respiratory function, predicted the rate of disease progression in ALS patients, suggesting the test could be used as a primary endpoint in clinical trials.
By injecting tau-enriched extracts derived from AD brains into transgenic mice, researchers dissect how Aβ plaques fuel tau pathology.
Alzheimer’s science has undergone a paradigm shift toward the disease’s silent phase. For trials, this means change at every level: new participants, new screening tools, new outcome measurements. What’s the progress?
Two complementary studies find that ApoE4 has little influence on plaques once they are present.
Tau’s apparent lockstep with cognitive decline dominated the PET conversation. Piramal flaunted data, and Merck/Cerveau are close behind. A first stab at imaging synapses in the hippocampus drew notice, too.
In people who carry a repeat expansion in the C9ORF72 gene, gray and white matter are smaller and subtle impairments in cognition appear decades before symptom onset.
Who doesn’t dread hours of testing at a clinic? Innovation needed! Learn about frequent “burst” testing via mobile app, and a digital pen that captures more information than the old paper-and-pencil test.
Recruitment, recruitment, recruitment: Registries get creative in how they promote research engagement and fill prevention trials.
Presented at CTAD, BACE inhibitor’s efficacy and safety results in mild to moderate AD were encouraging to some clinicians, vaguely disquieting to others.
Gradually raising the dose of this therapeutic antibody appears to ease the risk of brain inflammation.
In a Phase 2 trial in nursing home residents with Alzheimer’s, this new drug mitigated symptoms safely, without detriment to cognition.
Phase 1 trial tests the rejuvenating effects of young blood, while albumin replacement may offer its own benefits.
Ephemeral as they may be, these maligned peptides have become the targets of small-molecule and immunotherapies. Initial results of these efforts to catch and remove Aβ oligomers are trickling in.
According to a press release by trial sponsor Ionis, therapy was well tolerated, but trial results have yet to be released.
Besides the big-gun antibodies and BACE inhibitors, smaller, lesser-known drug programs are inching their way through the clinical trials pipeline. As is often the case, Phase 1 seems encouraging.
No filters selected